Literature DB >> 2330675

Analysis of retroviral packaging lines for generation of replication-competent virus.

D D Muenchau1, S M Freeman, K Cornetta, J A Zwiebel, W F Anderson.   

Abstract

Amplification of retroviral vector sequences occurs in cocultures of ecotropic and amphotropic packaging cell lines. Mixed packaging line cocultures were used to determine both the host range and time of appearance of replication-competent virus after introduction of a retroviral vector. Replication-competent virus was generated at a characteristic time for a given ecotropic and amphotropic packaging line combination. The time required to generate replication-competent virus in a packaging line varied with the number of recombination events necessary to generate replication-competent virus from the retroviral sequences present in the line. The psi 2 packaging line generated replication-competent virus within 10 days after transfection of the N2 vector into a mixture of psi 2 (ecotropic) and PA317 (amphotropic) packaging cells. Under the same conditions, it took only 3 days to develop replication-competent virus in psi 2/PA12 cocultures. The host range of replication-competent virus was used to identify the packaging line that initially generates virus. Each packaging line combination generated replication-competent virus at a characteristic time and this time period can be used as a measure of the "safety" of the packaging line and vector combination.

Mesh:

Substances:

Year:  1990        PMID: 2330675     DOI: 10.1016/0042-6822(90)90251-l

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  DNA methylation of helper virus increases genetic instability of retroviral vector producer cells.

Authors:  W B Young; G L Lindberg; C J Link
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Chimeric retroviral helper virus and picornavirus IRES sequence to eliminate DNA methylation for improved retroviral packaging cells.

Authors:  W B Young; C J Link
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Production of high-titer helper virus-free retroviral vectors by cocultivation of packaging cells with different host ranges.

Authors:  C M Lynch; A D Miller
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

4.  Replication-competent lentivirus analysis of clinical grade vector products.

Authors:  Kenneth Cornetta; Jing Yao; Aparna Jasti; Sue Koop; Makhaila Douglas; David Hsu; Larry A Couture; Troy Hawkins; Lisa Duffy
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

5.  Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research.

Authors:  Yasuhiro Takeuchi; Myra O McClure; Massimo Pizzato
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

Review 6.  Retroviral vectors. From laboratory tools to molecular medicine.

Authors:  R G Vile; A Tuszynski; S Castleden
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

7.  Homologous and nonhomologous retroviral recombinations are both involved in the transfer by infectious particles of defective avian leukosis virus-derived transcomplementing genomes.

Authors:  A Girod; A Drynda; F L Cosset; G Verdier; C Ronfort
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

Review 8.  Development of retroviral vectors as safe, targeted gene delivery systems.

Authors:  W H Günzburg; B Salmons
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

9.  Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Authors:  Kenneth Cornetta; Lisa Duffy; Cameron J Turtle; Michael Jensen; Stephen Forman; Gwendolyn Binder-Scholl; Terry Fry; Anne Chew; David G Maloney; Carl H June
Journal:  Mol Ther       Date:  2017-09-12       Impact factor: 11.454

10.  High-titer packaging cells producing recombinant retroviruses resistant to human serum.

Authors:  F L Cosset; Y Takeuchi; J L Battini; R A Weiss; M K Collins
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.